These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 21040805)
41. Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy. Chaplin DJ; Acker BD; Horsman MR Biomed Biochim Acta; 1989; 48(2-3):S264-8. PubMed ID: 2730621 [TBL] [Abstract][Full Text] [Related]
42. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours. Dalal S; Burchill SA Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249 [TBL] [Abstract][Full Text] [Related]
43. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Hill SA; Chaplin DJ; Lewis G; Tozer GM Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236 [TBL] [Abstract][Full Text] [Related]
44. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Murata R; Overgaard J; Horsman MR Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1018-24. PubMed ID: 11704326 [TBL] [Abstract][Full Text] [Related]
45. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Griggs J; Hesketh R; Smith GA; Brindle KM; Metcalfe JC; Thomas GA; Williams ED Br J Cancer; 2001 Mar; 84(6):832-5. PubMed ID: 11259100 [TBL] [Abstract][Full Text] [Related]
46. Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Davis PD; Tozer GM; Naylor MA; Thomson P; Lewis G; Hill SA Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1532-6. PubMed ID: 12459382 [TBL] [Abstract][Full Text] [Related]
47. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969 [TBL] [Abstract][Full Text] [Related]
48. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Beauregard DA; Hill SA; Chaplin DJ; Brindle KM Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555 [TBL] [Abstract][Full Text] [Related]
49. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Horsman MR; Ehrnrooth E; Ladekarl M; Overgaard J Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):895-8. PubMed ID: 9845117 [TBL] [Abstract][Full Text] [Related]
50. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Shibata MA; Akao Y; Shibata E; Nozawa Y; Ito T; Mishima S; Morimoto J; Otsuki Y Cancer Chemother Pharmacol; 2007 Oct; 60(5):681-91. PubMed ID: 17256131 [TBL] [Abstract][Full Text] [Related]
51. Combretastatin A-4 vascular damage to tumours. O'Brien C Mol Med Today; 1997 Sep; 3(9):369. PubMed ID: 9302685 [No Abstract] [Full Text] [Related]